71 Abstract This essay aims to examine the critical issues surrounding the application of the current Product Liability Directive (85/374/EEC) to damage resulting from medicinal products, especially when such damage stems from adverse effects inherent to the medicine itself. The analysis will then consider whether these challenges can be addressed by the new Product Liability Directive (EU) 2024/2853 and by the Italian liability provisions under art 2050 of the Civil Code.
Virginia Fusco (Tue,) studied this question.